Global Surufatinib Market Strategic Research Report

Scope of the Report

The global Surufatinib market size is predicted to grow from US$ 31.21 million in 2025 to US$ 65.39 million in 2032; it is expected to grow at a CAGR of 6.1% from 2026 to 2032.

.In 2025, global surufatinib production reached approximately 12.6 million units.Surufatinib is an oral small-molecule multi-target tyrosine kinase inhibitor (TKI), primarily used for the treatment of neuroendocrine tumors (NETs). It exerts its effects by simultaneously inhibiting multiple signaling pathways, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and colony-stimulating factor-1 receptor (CSF-1R), thereby providing dual anti-angiogenic and tumor immune-modulating activities, which suppress tumor growth and the immunosuppressive tumor microenvironment. Surufatinib is characterized by a multi-target synergistic mechanism, convenient oral administration, and broad-spectrum antitumor activity, making it clinically valuable in the treatment of advanced neuroendocrine tumors.

Surufatinib, as a multi-target tyrosine kinase inhibitor (TKI), operates within a relatively niche yet growing segment of the neuroendocrine tumor (NET) treatment market. With the increasing detection of NETs due to improved diagnostic methods and the advancement of precision medicine, the demand for targeted therapies continues to rise, providing a stable market foundation for surufatinib.From a competitive landscape perspective, targeted therapies and mTOR inhibitors such as Sunitinib and Everolimus currently dominate the market. However, surufatinib, with its multi-target mechanism acting on VEGFR, FGFR, and CSF-1R, as well as its differentiated advantage in modulating the tumor immune microenvironment, demonstrates competitive potential in specific patient populations.On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, although treatment options for neuroendocrine tumors remain relatively limited, the continuous development of new targeted therapies and immunotherapy regimens is gradually intensifying competition. Therefore, the future market performance of surufatinib will depend on its progress in expanding indications (such as additional NET subtypes or other solid tumors), developing combination treatment strategies, and accumulating real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and cost.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Surufatinib market?

What factors are driving Surufatinib market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Surufatinib market opportunities vary by end market size?

How does Surufatinib break out by Type, by Application?

This report presents a comprehensive overview of the global Surufatinib market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Hospital
• Retail Pharmacy
• Online Pharmacy

Segment by Application

• Neuroendocrine Tumor
• Anti-angiogenic Therapy
• Tumor Immune Microenvironment Modulation
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Surufatinib market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Neuroendocrine Tumor, Anti-angiogenic Therapy, Tumor Immune Microenvironment Modulation evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact